CIA
GNMK

Capital Impact Advisors’s GenMark Diagnostics, Inc GNMK Stock Holding History

Capital Impact Advisors’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-13,933
Closed -$190K – 317
2014
Q4 		$190K Hold
13,933
– – 0.09% 123
2014
Q3 		$125 Hold
13,933
– – ﹤0.01% 194
2014
Q2 		$189K Buy
+13,933
New +$145K 0.14% 97

Other funds holding GNMK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Impact Advisors's GNMK Position: Q1 2015 in Review

Capital Impact Advisors sold out of GenMark Diagnostics, Inc (GNMK) in Q1 2015, closing a stake of 13,933 shares — an estimated $190K sold.

Capital Impact Advisors first reported a position in GNMK in Q2 2014 and held it in 3 quarters. The position peaked at $190K in Q4 2014. 80 funds tracked by Wall St. Rank hold GNMK as of Q1 2015.

  • Capital Impact Advisors reported no remaining GenMark Diagnostics, Inc position as of Q1 2015 after selling out during the quarter.
  • Capital Impact Advisors sold 13,933 GenMark Diagnostics, Inc shares in Q1 2015, an estimated $190K.
  • Capital Impact Advisors first reported a position in GenMark Diagnostics, Inc in Q2 2014 and held it in 3 quarters.
  • Capital Impact Advisors's GenMark Diagnostics, Inc position peaked at $190K in Q4 2014.
  • 80 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q1 2015.

Based on Capital Impact Advisors's 13F filing for Q1 2015, filed 29 May 2015.